In addition, NF‐κB signalling could also induce the secretion of CXCL1 and the recruitment of CXCR2 + MDSCs into CRC tumours, thus impairing effective T cell responses during anti‐PD1 therapy [40]. The gene discussed is CXCR2; the disease is colorectal carcinoma.